Spravato
We are proud to offer Spravato (esketamine) as a treatment option for eligible patients. Spravato is an FDA-approved medication used in conjunction with an oral antidepressant for adults with treatment-resistant depression (TRD) and major depressive disorder (MDD) with suicidal ideation. Our experienced healthcare professionals are trained to administer Spravato safely and monitor patients throughout their treatment journey. We are dedicated to providing compassionate care and exploring innovative solutions to improve the mental health and well-being of our patients.
What is SPRAVATO® (esketamine) CIII nasal spray?
SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat:
Adults with treatment-resistant depression (TRD)
Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions
SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.
It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.
It is not known if SPRAVATO® is safe and effective in children.
For more information about SPRAVATO and its side effects click the learn more button.
What is Treatment Resistant Depression?
Taking an antidepressant or going to psychological counseling (psychotherapy) eases depression symptoms for most people. But with treatment-resistant depression, standard treatments aren’t enough. They may not help much at all, or your symptoms may improve, only to keep coming back.
Treatment-resistant depression symptoms can range from mild to severe and may require trying a number of approaches to identify what helps.
For more information on treatment resistant depression click the learn more button.
How is Spravato administered?
Nasal spray you self-administer under the supervision of a healthcare provider. After you take SPRAVATO®, a healthcare provider will monitor you have an observation period. During the observation period you will be allowed to rest comfortably, and a healthcare provider will check for any treatment side effects that you might experience. The observation period will last for at least two hours. Sedation (feeling sleepy) and dissociation (feeling disconnected from yourself, your thoughts, feelings and things around you) are among the possible serious side effects during and after taking SPRAVATO®, and you should expect your healthcare provider to ask you about these possible side effects during this period. Your blood pressure will be checked periodically during the observation period, as some people treated with SPRAVATO® have a temporary increase in blood pressure after treatment.